Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report

IF 1.5 Q4 ONCOLOGY

Cancer reports Pub Date : 2025-06-11 DOI:10.1002/cnr2.70238

Maud B. A. van der Kleij, Tristan V. M. Bruijn, Raween W. Kalicharan, Yannick S. Elshot, Maxime C. F. Pilon, Mark Oostdijk, Matthijs M. Tibben, Bastiaan Nuijen, Alwin D. R. Huitema, Thomas Rustemeyer, Neeltje Steeghs

{"title":"Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report","authors":"Maud B. A. van der Kleij, Tristan V. M. Bruijn, Raween W. Kalicharan, Yannick S. Elshot, Maxime C. F. Pilon, Mark Oostdijk, Matthijs M. Tibben, Bastiaan Nuijen, Alwin D. R. Huitema, Thomas Rustemeyer, Neeltje Steeghs","doi":"10.1002/cnr2.70238","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Imatinib treatment is approved for several indications, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Although adverse events are common, hypersensitivity reactions are not. Because there is a clear clinical benefit of imatinib treatment, re-introduction of imatinib after a hypersensitivity reaction should be considered.</p>\n </section>\n \n <section>\n \n <h3> Case</h3>\n \n <p>Here we present a case report of a 68-year-old patient with a GIST diagnosis who was re-introduced to imatinib after a type IV hypersensitivity reaction via desensitization. A desensitization plan, a plan for formulation of low-dose imatinib capsules, and the essential steps when considering desensitization are discussed.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our case of a patient with a type IV hypersensitivity reaction after starting imatinib treatment demonstrates that desensitization is a feasible option after serious cutaneous adverse events in specific cases, when done with good interdisciplinary collaboration and clinical management.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70238","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Imatinib treatment is approved for several indications, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Although adverse events are common, hypersensitivity reactions are not. Because there is a clear clinical benefit of imatinib treatment, re-introduction of imatinib after a hypersensitivity reaction should be considered.

Case

Here we present a case report of a 68-year-old patient with a GIST diagnosis who was re-introduced to imatinib after a type IV hypersensitivity reaction via desensitization. A desensitization plan, a plan for formulation of low-dose imatinib capsules, and the essential steps when considering desensitization are discussed.

Conclusion

Our case of a patient with a type IV hypersensitivity reaction after starting imatinib treatment demonstrates that desensitization is a feasible option after serious cutaneous adverse events in specific cases, when done with good interdisciplinary collaboration and clinical management.

查看原文本刊更多论文

胃肠道间质瘤患者IV型超敏反应后伊马替尼脱敏1例报告

伊马替尼治疗已被批准用于多种适应症，包括慢性髓性白血病（CML）和胃肠道间质瘤（GIST）。虽然不良事件很常见，但过敏反应却不常见。由于伊马替尼治疗有明显的临床益处，应考虑在过敏反应后再次引入伊马替尼。在这里，我们提出了一个病例报告，68岁的胃肠道间质瘤患者诊断后，通过脱敏的IV型超敏反应再次引入伊马替尼。本文讨论了脱敏计划，低剂量伊马替尼胶囊的配方计划，以及考虑脱敏的基本步骤。结论我们的病例是一名开始伊马替尼治疗后出现IV型超敏反应的患者，这表明在特殊情况下，在良好的跨学科合作和临床管理下，脱敏是严重皮肤不良事件后的可行选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊